Abstract | OBJECTIVE: DATA SOURCES: A MEDLINE search (1966-February 2013) was conducted for English-language studies in humans, using the terms rivoglitazone and CS011. Abstracts presented at the American Diabetes Association and European Association for the Study of Diabetes annual meetings from 2007 to 2012 were also evaluated for relevant data. STUDY SELECTION AND DATA EXTRACTION: Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of rivoglitazone were reviewed. DATA SYNTHESIS: CONCLUSIONS:
Rivoglitazone is the fourth agent in the thiazolidinedione class of antidiabetes drugs. Although rivoglitazone appears to be more potent in its ability to lower A1C levels compared with other thiazolidinediones, further studies of longer duration are needed to fully assess the risks associated with this drug. Until these can be completed, we cannot recommend rivoglitazone over currently approved drugs in this class.
|
Authors | Robin L Koffarnus, Kurt A Wargo, Haley M Phillippe |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 47
Issue 6
Pg. 877-85
(Jun 2013)
ISSN: 1542-6270 [Electronic] United States |
PMID | 23632280
(Publication Type: Journal Article, Review)
|
Chemical References |
- Glycated Hemoglobin A
- PPAR gamma
- Thiazolidinediones
- hemoglobin A1c protein, human
- rivoglitazone
- 2,4-thiazolidinedione
|
Topics |
- Animals
- Diabetes Mellitus, Type 2
(drug therapy, metabolism)
- Glycated Hemoglobin
(antagonists & inhibitors)
- Humans
- PPAR gamma
(agonists, metabolism)
- Randomized Controlled Trials as Topic
(methods)
- Thiazolidinediones
(pharmacology, therapeutic use)
- Treatment Outcome
|